Updates | CaaMTech

November 14, 2024

FDA Blesses CaaMTech’s Psychedelic Functional Unblinding Strategy

CaaMTech’s new clinical trial design solves the emergent functional unblinding problems plaguing psychedelic medicine developers

March 27, 2024

Dr. Nathan Sackett Joins CaaMTech to Advise on Neuropsychiatry

Dr. Sackett also serves as the Director of the University of Washington Center for Novel Therapeutics in Addiction Psychiatry

September 21, 2023

CaaMTech Collaboration Investigates Terpene Production in Magic Mushrooms

Genomic sequences of various Psilocybe species revealed an unexpected wealth of genes encoding sesquiterpene synthases

September 14, 2023

CaaMTech CEO to Present at ACS Meeting

The American Chemical Society will host the Chemistry of Psychedelics symposium at the 2023 Rocky Mountain Regional Meeting Sept. 14–17 the University of Wyoming

September 12, 2023

CaaMTech Crystallography Collaboration Clarifies Chemical Characterization Confusion

The publication of the crystal structure of 4-AcO-EPT fumarate fumaric acid also exemplifies CaaMTech’s pioneering tryptamine prodrug and SAR research

Bis4-acetoxy-N-ethyl-N-n-propyltryptammonium-fumarate–fumaric-acid.

August 4, 2023

CaaMTech and University of Massachusetts Dartmouth Collaborate to Research N-Cyclohexyltryptamine Structures

Dialkyl tryptamines have received widespread attention for their potential to treat numerous mood disorders. But secondary tryptamines, or monoalkyl tryptamines, have received almost no such attention.